

Mexico Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2026-2034

<https://marketpublishers.com/r/M76CA1F67946EN.html>

Date: June 2026

Pages: 118

Price: US\$ 2,999.00 (Single User License)

ID: M76CA1F67946EN

Abstracts

The Mexico cancer immunotherapy market size reached USD 1.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.6 Billion by 2034, exhibiting a growth rate (CAGR) of 8.41% during 2026-2034. The market is expanding with the increased application of checkpoint inhibitors, cancer vaccine uses expanded, and multipurpose roles of immunomodulators across a range of cancers. The treatments are becoming part of national oncology standards, led by clinical need and immune-based therapy advances. As adoption amplifies and applications expand among different cancers, the Mexico cancer immunotherapy market share continues to grow steadily and strategically.

MEXICO CANCER IMMUNOTHERAPY MARKET TRENDS:

Growing Use of Checkpoint Inhibitors

Mexico is seeing a sharp rise in the use of checkpoint inhibitors as they prove to be effective in curing other types of cancer as well, most notably melanoma and non-small cell lung cancer. They attack the cancer cells by optimizing the ability of the immune system to identify and kill the cancer cells, providing longer remission than traditional cancer treatments. Public and private healthcare facilities are highly adopting checkpoint inhibitor therapies as part of routine treatment protocols, a move towards personalized medicine. Immune-based regimens are now the preferred clinical protocols, especially among patients who are resistant to chemotherapy or radiation. Mexico cancer immunotherapy market growth continue to look good as patient demand and medical awareness evolve in parallel. As per the sources. in March 2023, Mexico started CAR-T cell therapy clinical trials for blood cancers at Dr. Jos? Eleuterio

González Hospital, UANL, in collaboration with ImmunoACT, National Polytechnic Institute, and Salvador Zubirán Institute. Furthermore, progress in diagnostic technologies and availability of biomarker testing has further facilitated the rational use of these therapies, solidifying their inclusion in treatment guidelines. Increasing dependence on immune checkpoint inhibitors is remodeling the therapeutic paradigm and raising the bar for cancer treatment in Mexico.

Cancer Vaccine Expansion

The vaccine against cancer is slowly growing in Mexico, being boosted by increased investments in prevention and therapeutic approaches to immunization. The vaccines are being explored and used for not just cervical and liver cancer but are reaching the investigative stage for lung and colorectal cancers. The need is fueled by a mix of local epidemiologic evidence and an urgent need to induce long-lasting immune memory for tumor antigens. Health authority programs and educational campaigns are contributing to raising awareness and early diagnosis, which will be critical in the successful administration of therapeutic cancer vaccines. Research centers are also actively involved in trials examining vaccine effectiveness in conjunction with other immunotherapies. As healthcare policy continues to favor advanced oncology care, Mexico cancer immunotherapy development is projected to pick up pace. The emphasis on targeted and immune-based therapies is setting the stage for cancer vaccines to become an accepted part of immuno-oncology standard practice in the nation.

Diversification of Immunomodulator Use Across Cancer Types

Immunomodulators, which have long been employed to manipulate immune response, are increasingly being used in diverse forms of cancer in Mexico, such as breast, prostate, and head and neck cancers. For instance, in July 2024, Zydus Lifesciences introduced its Bevacizumab biosimilar in Mexico, while CAR-T trials, CHIPSA's treatments, and Immunocine's dendritic cell therapies broadened immunotherapy choices in 2023–2024. Moreover, these drugs are being more commonly incorporated into multimodal treatment regimens as adjuncts to surgery, radiation, and chemotherapy. Their capacity to rebalance immune function makes them especially useful in cancers that are otherwise unresponsive to other types of immunotherapies. With growing clinical insights into tumor microenvironments, immunomodulators are being redesigned for more selective application, optimizing patient outcomes. Physicians are also investigating sequential and combination treatments including immunomodulators to prevent treatment resistance. Growing clinical uptake of these therapies has resulted in their inclusion within national treatment guidelines. Mexico

cancer immunotherapy share is therefore continuously growing, underpinned by developments in formulation technologies and immune profiling. The trend indicates a developing environment where the manipulation of immune systems is core to obtaining extended therapeutic effects in oncology.

MEXICO CANCER IMMUNOTHERAPY MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on therapy type, application, and end user.

Therapy Type Insights:

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Others

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators, others.

Application Insights:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and Neck Cancer

Others

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others.

End User Insights:

Hospitals

Cancer Research Centers

Clinics

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, cancer research centers, clinics, and others.

Regional Insights:

Northern Mexico

Central Mexico

Southern Mexico

Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico, and Others.

COMPETITIVE LANDSCAPE:

Mexico Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, an...

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT

How has the Mexico cancer immunotherapy market performed so far and how will it perform in the coming years?

What is the breakup of the Mexico cancer immunotherapy market on the basis of therapy type?

What is the breakup of the Mexico cancer immunotherapy market on the basis of application?

What is the breakup of the Mexico cancer immunotherapy market on the basis of end user?

What is the breakup of the Mexico cancer immunotherapy market on the basis of region?

What are the various stages in the value chain of the Mexico cancer immunotherapy market?

What are the key driving factors and challenges in the Mexico cancer immunotherapy?

What is the structure of the Mexico cancer immunotherapy market and who are the key players?

What is the degree of competition in the Mexico cancer immunotherapy market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MEXICO CANCER IMMUNOTHERAPY MARKET - INTRODUCTION

- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence

5 MEXICO CANCER IMMUNOTHERAPY MARKET LANDSCAPE

- 5.1 Historical and Current Market Trends (2020-2025)
- 5.2 Market Forecast (2026-2034)

6 MEXICO CANCER IMMUNOTHERAPY MARKET - BREAKUP BY THERAPY TYPE

- 6.1 Monoclonal Antibodies
 - 6.1.1 Overview
 - 6.1.2 Historical and Current Market Trends (2020-2025)
 - 6.1.3 Market Forecast (2026-2034)
- 6.2 Cancer Vaccines
 - 6.2.1 Overview
 - 6.2.2 Historical and Current Market Trends (2020-2025)

6.2.3 Market Forecast (2026-2034)

6.3 Checkpoint Inhibitors

6.3.1 Overview

6.3.2 Historical and Current Market Trends (2020-2025)

6.3.3 Market Forecast (2026-2034)

6.4 Immunomodulators

6.4.1 Overview

6.4.2 Historical and Current Market Trends (2020-2025)

6.4.3 Market Forecast (2026-2034)

6.5 Others

6.5.1 Historical and Current Market Trends (2020-2025)

6.5.2 Market Forecast (2026-2034)

7 MEXICO CANCER IMMUNOTHERAPY MARKET - BREAKUP BY APPLICATION

7.1 Lung Cancer

7.1.1 Overview

7.1.2 Historical and Current Market Trends (2020-2025)

7.1.3 Market Forecast (2026-2034)

7.2 Breast Cancer

7.2.1 Overview

7.2.2 Historical and Current Market Trends (2020-2025)

7.2.3 Market Forecast (2026-2034)

7.3 Colorectal Cancer

7.3.1 Overview

7.3.2 Historical and Current Market Trends (2020-2025)

7.3.3 Market Forecast (2026-2034)

7.4 Melanoma

7.4.1 Overview

7.4.2 Historical and Current Market Trends (2020-2025)

7.4.3 Market Forecast (2026-2034)

7.5 Prostate Cancer

7.5.1 Overview

7.5.2 Historical and Current Market Trends (2020-2025)

7.5.3 Market Forecast (2026-2034)

7.6 Head and Neck Cancer

7.6.1 Overview

7.6.2 Historical and Current Market Trends (2020-2025)

7.6.3 Market Forecast (2026-2034)

7.7 Others

7.7.1 Historical and Current Market Trends (2020-2025)

7.7.2 Market Forecast (2026-2034)

8 MEXICO CANCER IMMUNOTHERAPY MARKET - BREAKUP BY END USER

8.1 Hospitals

8.1.1 Overview

8.1.2 Historical and Current Market Trends (2020-2025)

8.1.3 Market Forecast (2026-2034)

8.2 Cancer Research Centers

8.2.1 Overview

8.2.2 Historical and Current Market Trends (2020-2025)

8.2.3 Market Forecast (2026-2034)

8.3 Clinics

8.3.1 Overview

8.3.2 Historical and Current Market Trends (2020-2025)

8.3.3 Market Forecast (2026-2034)

8.4 Others

8.4.1 Historical and Current Market Trends (2020-2025)

8.4.2 Market Forecast (2026-2034)

9 MEXICO CANCER IMMUNOTHERAPY MARKET – BREAKUP BY REGION

9.1 Northern Mexico

9.1.1 Overview

9.1.2 Historical and Current Market Trends (2020-2025)

9.1.3 Market Breakup by Therapy Type

9.1.4 Market Breakup by Application

9.1.5 Market Breakup by End User

9.1.6 Key Players

9.1.7 Market Forecast (2026-2034)

9.2 Central Mexico

9.2.1 Overview

9.2.2 Historical and Current Market Trends (2020-2025)

9.2.3 Market Breakup by Therapy Type

9.2.4 Market Breakup by Application

9.2.5 Market Breakup by End User

9.2.6 Key Players

9.2.7 Market Forecast (2026-2034)

9.3 Southern Mexico

9.3.1 Overview

9.3.2 Historical and Current Market Trends (2020-2025)

9.3.3 Market Breakup by Therapy Type

9.3.4 Market Breakup by Application

9.3.5 Market Breakup by End User

9.3.6 Key Players

9.3.7 Market Forecast (2026-2034)

9.4 Others

9.4.1 Historical and Current Market Trends (2020-2025)

9.4.2 Market Forecast (2026-2034)

10 MEXICO CANCER IMMUNOTHERAPY MARKET – COMPETITIVE LANDSCAPE

10.1 Overview

10.2 Market Structure

10.3 Market Player Positioning

10.4 Top Winning Strategies

10.5 Competitive Dashboard

10.6 Company Evaluation Quadrant

11 PROFILES OF KEY PLAYERS

11.1 Company A

11.1.1 Business Overview

11.1.2 Products Offered

11.1.3 Business Strategies

11.1.4 SWOT Analysis

11.1.5 Major News and Events

11.2 Company B

11.2.1 Business Overview

11.2.2 Products Offered

11.2.3 Business Strategies

11.2.4 SWOT Analysis

11.2.5 Major News and Events

11.3 Company C

11.3.1 Business Overview

11.3.2 Products Offered

- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
- 11.4 Company D
 - 11.4.1 Business Overview
 - 11.4.2 Products Offered
 - 11.4.3 Business Strategies
 - 11.4.4 SWOT Analysis
 - 11.4.5 Major News and Events
- 11.5 Company E
 - 11.5.1 Business Overview
 - 11.5.2 Products Offered
 - 11.5.3 Business Strategies
 - 11.5.4 SWOT Analysis
 - 11.5.5 Major News and Events

12 MEXICO CANCER IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS

- 12.1 Drivers, Restraints, and Opportunities
 - 12.1.1 Overview
 - 12.1.2 Drivers
 - 12.1.3 Restraints
 - 12.1.4 Opportunities
- 12.2 Porters Five Forces Analysis
 - 12.2.1 Overview
 - 12.2.2 Bargaining Power of Buyers
 - 12.2.3 Bargaining Power of Suppliers
 - 12.2.4 Degree of Competition
 - 12.2.5 Threat of New Entrants
 - 12.2.6 Threat of Substitutes
- 12.3 Value Chain Analysis

13 APPENDIX

I would like to order

Product name: Mexico Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/M76CA1F67946EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M76CA1F67946EN.html>